Novartis drug cuts multiple sclerosis relapse rates by about a third in Phase 3 trials
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
In two Phase 3 trials, Novartis’s remibrutinib reduced annualized relapse rates in relapsing multiple sclerosis by 35.2% and 31.2% versus Sanofi’s Aubagio—about one relapse every 13 years. Roche’s fenebrutinib exceeded 50%, but remibrutinib had a cleaner safety profile.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu